Table 1.

Most common benign and malignant types of neoplasms in different studies.

Registry	Australia [15] #, N = 1000	Australia [16] #, N = 1000	Greece [10] #, N = 174	Korea [17] #, N = 748
Distribution benign/malignant	B: 41.9% M: 58.1%	B: 48.2% M: 52.8%	B: 53.4% M: 46.6%	B: 69% M: 31%
Top 3 benign Pct of all skin tumours (Pct of all benign tumours)	Basal cell tumour 12.0% (20.7%) Perianal gl. adenomas 8.3% (19.8%) Histiocytoma 7.8% (18.6%)	Histiocytoma 14.0% (29.0%) Lipoma 6.0% (12.4%) Basal cell epithelioma 5.5% (11.4%)	Hepato gl. adenoma 9.8% (18.3%) Lipoma 5.7% (10.8%) Histiocytoma 5.7% (10.8%)	Epidermal cysts 12.7% (18.3%) Lipoma 11.4% (16.4%) Histiocytoma 7.5% (10.8%)
Top 3 malignant Pct of total skin (pct of all malignant skin tumours)	MCT 17.6% (30.3%) STS 8.5% (14.6%) Melanoma 6.8% (11.7%)	MCT 16.1% (31.1%) STS 14.4% (27.8%) SCC 6.9% (13.3%)	MCT 13.8% (29.6%) STS 10.3% (22.2%) Basal cell carcinoma 4.0% (8.6%)	MCT 8.8% (28.7%) STS 3.3% (10.9%) Apocrine adenocarcinoma 3.1% (10.0%)
Registry		Norway [1] #, N = 7401	South Africa [18] #; N = 903	USA [3] #, N = 277
Distribution benign/malignant		M: 22%	B: 54.4% M: 45.6%	M: 100%
Top 3 benign Pct of all skin tumours (Pct of all benign tumours)		Epidermal adenoma 22.7% (29.2%) Lipoma 13.6% (17.4%) Histiocytoma 13.3% (17.1%)	Basal cell tumour 18.8% (34.6%) Perineal gland adenoma 13.4% (24.6%) Sebaceous gland adenomas and cysts 6.1% (11.2%)	-
Top 3 malignant Pct of total skin (pct of all malignant skin tumours)		MCT 10.0 (45.4%) STS 4.3% (19.6%) Malignant epidermal tumours 3.4% (15.4%)	SCC 16.4% (35.9%) Melanoma 11.4% (25.0%) MCT 8.9% (19.4%)	MCT (27%) Adenocarcinoma (26%) Melanoma (22%)

MCT: Mast cell tumours, SCC: Squamous cell carcinoma, STS: Soft tissue sarcoma